Drugs / Trivalent Influenza Vaccine 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04210349 | Jan → Dec 2020 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Vaccine 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04210349 ↗ |
| Known as | SP Shz TIV2 | “Trivalent Influenza Vaccine 2 SP Shz TIV2” NCT04210349 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular” NCT04210349 ↗ |